Xenikos secures USD30m in Series B financing
Xenikos, a clinical-stage biopharmaceutical company currently developing a novel therapy for treating acute graft-versus-host disease (aGVHD), has secured USD30 million in a Series B financing round. Two new investors in the company – Medicxi Ventures and RA Capital Management – participated in the financing round. The funds will be used